OncoMatch/Clinical Trials/NCT07004244
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Is NCT07004244 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including KRAS-mutated mRNA vaccine and TORIPALIMAB for malignant tumors.
Treatment: KRAS-mutated mRNA vaccine · TORIPALIMAB · Pemetrexed+carboplatin — The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS any mutation
Required: KRAS g12c
Required: KRAS g12d
Required: KRAS g12v
Required: KRAS g13d
Disease stage
Required: Stage IB, IIA, IIB, IIIA (AJCC 9th edition)
Resectable disease classified as stage IB-IIIA per AJCC 9th edition criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor therapy
Exception: allowed if >4 weeks prior to first dose and all adverse reactions resolved to ≤ grade 1 (except alopecia)
Patients who received anti-tumor therapy within 4 weeks prior to the first dose, or those with unresolved adverse reactions (except alopecia) from prior anti-tumor therapy (NCI CTCAE > grade 1).
Cannot have received: same class as investigational drug
Participants who received drugs of the same class within 6 months prior to the first dose.
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify